Last updated: 2026-09-08 22:34:00. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Cardiff Oncology, Inc. (CRDF) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $1.11, with a market capitalization of $84.80M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.76 to $3.31. This page covers its latest market performance, valuation, price trends and company information.
$84.80M | |
$1.05 | |
$25.50 | |
$0.76 | |
$1.09 | |
693.15K | |
1.23M | |
-- | |
$3.31 | |
$0.76 | |
-- | |
-- |
Cardiff Oncology, Inc. (CRDF) is trading at $1.09 in after-hours trading as of 2026-09-08 22:21:00, unchanged from the regular-session close of $1.09.
After-hours trading shows how investors are pricing CRDF after the regular session closes. The current after-hours price is near the regular-session close, indicating neutral after-hours sentiment.
Over the past seven days, Cardiff Oncology, Inc. (CRDF) moved from $0.99 to $1.11, representing a gain of 12.06% ($0.12).
The stock traded between $0.90 and $1.13 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 525.63 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 13.6%
CRDF is currently trading at $1.11, placing it 13.6% of the way from its 52-week low of $0.76 to its 52-week high of $3.31. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Cardiff Oncology Inc is a clinical-stage biotechnology company advancing cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Its main asset, onvansertib, is a specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, to overcome treatment resistance and deliver improved clinical outcomes for patients.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 31 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Cardiff Oncology, Inc. (CRDF) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.